Yasuhisa Murai

TL;DR: In this article, a new ATR-based chemotherapy drug, M4344, was proposed and compared with the clinically developed ATR inhibitors BAY1895344, berzosertib, and ceralasertib using in vitro and in vivo models.

TL;DR: In this paper, the authors performed an unbiased genome-wide RNAi screen in SLFN11-WT and -knockout (KO) cells and found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in cancer cells.

TL;DR: In this article, the authors conducted a drug screen with the NCATS mechanistic drug library of 1,978 compounds in isogenic SLFN11-knockout (KO) and wild-type (WT) leukemia cell lines and found that TAK-243, a first-in-class ubiquitin activating enzyme UBA1 inhibitor in clinical development, causes preferential cytotoxicity in SLFN-11-KO cells; this effect is associated with claspin-mediated DNA replication inhibition by CHK1 independently of ATR.

TL;DR: In this paper, the role of Spartan (SPRTN) is explored for DNA replication in human TK6 and chicken DT40 lymphoblastoid cells, and it is shown that SPRTN-deficient cells are hypersensitive to talazoparib and olaparib, but not to veliparib.